• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Inspections, Compliance, Enforcement, and Criminal Investigations

  • Print
  • Share
  • E-mail

Section Contents Menu

Enforcement Actions

Rose Stone Enterprises dba Hub Pharmaceuticals LLC 11/16/11

  

Department of Health and Human Services logoDepartment of Health and Human Services

Public Health Service
Food and Drug Administration
 Los Angeles District
Pacific Region
19701 Fairchild
Irvine, CA 92612-2506
Telephone: 949-798-2900
FAX: 949-798-4415 

 

WARNING LETTER


CERTIFIED MAIL
RETURN RECEIPT REQUESTED


November 16, 2011

W/L 05-12
 


Ms. Cyndy Rosenstein
President and CEO
Hub Pharmaceuticals, LLC
9939 Charles Smith Ave.
Rancho Cucamonga, CA 91730


Products: Fluorescein Sodium Injections


Dear Ms. Rosenstein:
 

We are writing in reference to your firm's distributing unapproved new drugs in violation of the Federal Food, Drug, and Cosmetic Act (the Act). Based on the information your firm submitted to FDA's Drug-Registration and Listing System, you distribute for (b)(4), the following prescription drugs:


• Fluorescein Injection 250 mg/ml (Fluorescein Injection U.S.P. Lite 25%)
• Fluorescein Injection 100 mg/ml (Fluorescein Injection U.S.P. Lite 10%)
• Fluorescein Injection 250 mg/ml (Fluorescein Injection U.S.P. Dark 25%)
• Fluorescein Injection 100 mg/ml (Fluorescein Injection U.S.P. Dark 10%)


As labeled, these products are drugs within the meaning of section 201(g)(1)(B) and (C) of the Act [21 U.S.C. §§ 321(g)(1)(B) and (C)] because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease and because they are intended to affect the structure or function of the body of man or other animals. Further, these drug products, as distributed by your firm, are "new drugs" within the meaning of section 201(p) of the Act [21 U.S.C. § 321(p)] because they are not generally recognized as safe and effective for their labeled uses. Under sections 301(d) and 505(a) of the Act [21 U.S.C. §§ 331(d) and 355(a)], a new drug may not be introduced or delivered for introduction into interstate commerce unless it is the subject of an application approved by FDA under either section 505(b) or G) of the Act [21 U.S.C. § 355(b) or G)]. There are no FDA-approved applications on file for these products.


Distributing these products or any other new drugs without approved applications therefore violates these provisions of the Act. 

 

Additionally, because the above products are prescription drugs within the meaning of section 503(b)(1) of the Act [21 U.S.C. 353(b)(1)], adequate directions cannot be written so that a layman can use these products safely for their intended uses. See 21 C.F.R. § 201.5. Consequently, their labeling fails to bear adequate directions for their intended uses, causing them to be misbranded under section 502(f)(1) of the Act [21 U.S.C. § 352(f)(1)]. Because your products lack required approved applications, they are not exempt under 21 C.F.R. § 201.115 from the requirements of section 502(f)(1) of the Act. The introduction or delivery for introduction into interstate commerce of these products therefore violates section 301(a) of the Act [21 U.S.C. § 331(a)].


Consistent with its "Marketed Unapproved Drugs - Compliance Policy Guide,''1 FDA does not intend to initiate enforcement action related to your unapproved fluorescein drug products, unless the manufacturing of these products continues more than 90 days after the date of this letter. Furthermore, FDA does not intend to initiate enforcement action related to the shipment in interstate commerce of these products unless they are still being distributed more than 180 days after the date of this letter.


You should be aware that FDA's enforcement discretion will not apply if (1) FDA determines that your firm is violating other provisions of the Act; (2) it appears that your firm, in response to this letter, increases its manufacture or distribution of your unapproved fluorescein drug products above your usual volume during these periods; or (3) FDA learns of new information regarding any serious health risk or hazard associated with these drug products.


The violations cited in this letter are not necessarily limited to drug products manufactured for your firm by (b)(4) and may apply to all drug products that you distribute without FDA-approved applications. You are responsible for (1) investigating and determining the causes of the violations identified above; (2) preventing their recurrence or the occurrence of other violations; and (3) assuring that your firm complies with all requirements of Federal law and FDA regulations.


You should take prompt action to correct the violations cited in this letter. Within fifteen (15) working days of receipt of this letter, please notify this office in writing whether you plan to cease the violative activities described in this letter. Indicate:
 

• whether you no longer distribute the product referenced in this letter;
• the reasons for, and the date on which, you ceased distribution;
• the name and address of any other manufacturer or supplier of these products; and
• your progress updating FDA's Drug Registration and Listing System in accordance with 21 C.F.R. 207.30(a)(2). See (http://www.fda.gov/Drugs/InformationOnDrugs/ucm142438.htm).


Failure to promptly correct these violations may result in legal action without further notice, including, without limitation, seizure and injunction. Other Federal agencies may take this Warning Letter into account when awarding contracts.

Your written reply should be directed to:


Blake Bevill
Director Compliance Branch
Los Angeles District
U.S. Food and Drug Administration
19701 Fairchild
Irvine, CA 92612


If you have any questions regarding this letter, please contact Mr. John Stamp, Compliance Officer at 949-608-4464.


Sincerely,
/S/
Alonza E. Cruse
District Director
Los Angeles 

 

1 Marketed Unapproved Drugs- Compliance Policy Guide. Available at http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatorylnformation/Guidances/UCM070290.pdf